Figure 3.
BVRA enzymatic activity is repressed in Blvra G17A and Blvra E97A mutant mice
(A and B) Ex-vivo BVRA enzymatic activity in tissue homogenates from BlvraG17A mice. (A) Time course of bilirubin production measured as bilirubin concentration (nM/μg protein) over 50 min in spleen (left), kidney (middle), and liver (right) from BlvraWT, Blvra−/−, and BlvraG17A mice. (B) Area under the curve (AUC) analysis spleen (left), kidney (middle), and liver (right) comparing enzymatic activity between genotypes.
(C and D) Ex-vivo BVRA enzymatic activity in tissue homogenates from BlvraE97A mice. (C) Time course of bilirubin production measured as BR concentration (nM/μg protein) over 50 min in spleen (left), kidney (middle), and liver (right) from BlvraWT, Blvra−/−, and BlvraG17A mice. (D) Area under the curve (AUC) analysis for spleen (left), kidney (middle), and liver (right) comparing enzymatic activity between genotypes. Data represent mean ± SD. n = 3 mice per genotype. Statistical comparisons were performed using one-way ANOVA with post hoc test. ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001; NS, not significant. (A and B) Ex vivo BVRA activity from BlvraG17A mice. (C and D) Ex vivo BVRA activity from BlvraE97A mice. Mean ± SD. n = 3 per genotype. One-way ANOVA. ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001; NS, not significant.
